Difference between revisions of "Classification of urothelial carcinoma by immunohistochemistry"
Jump to navigation
Jump to search
| Line 5: | Line 5: | ||
==General== | ==General== | ||
*A large meta-analysis showed two markers (CK5/6, GATA3) can subclassify ~90% of urothelial carcinoma into prognostic groups.<ref>{{cite journal |authors=Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, Guo CC, Dinney C, Cogdell DE, Zhang S, Lee S, Lee JG, Weinstein JN, Baggerly K, McConkey D, Czerniak B |title=Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use |journal=EBioMedicine |volume=12 |issue= |pages=105–117 |date=October 2016 |pmid=27612592 |pmc=5078592 |doi=10.1016/j.ebiom.2016.08.036 |url=}}</ref> | *A large meta-analysis showed two markers (CK5/6, GATA3) can subclassify ~90% of urothelial carcinoma into prognostic groups.<ref>{{cite journal |authors=Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, Guo CC, Dinney C, Cogdell DE, Zhang S, Lee S, Lee JG, Weinstein JN, Baggerly K, McConkey D, Czerniak B |title=Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use |journal=EBioMedicine |volume=12 |issue= |pages=105–117 |date=October 2016 |pmid=27612592 |pmc=5078592 |doi=10.1016/j.ebiom.2016.08.036 |url=}}</ref> | ||
===Prognosis=== | |||
'''B'''asal is '''b'''ad.<ref pmid=27612592>{{cite journal |authors=Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, Guo CC, Dinney C, Cogdell DE, Zhang S, Lee S, Lee JG, Weinstein JN, Baggerly K, McConkey D, Czerniak B |title=Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use |journal=EBioMedicine |volume=12 |issue= |pages=105–117 |date=October 2016 |pmid=27612592 |pmc=5078592 |doi=10.1016/j.ebiom.2016.08.036 |url=}}</ref> | |||
===A simple classification of urothelial carcinoma by immunohistochemistry=== | ===A simple classification of urothelial carcinoma by immunohistochemistry=== | ||
Revision as of 18:00, 8 March 2024
A classification of urothelial carcinoma by immunohistochemistry can be done with three immunostains.[1]
UCC IHC classification redirects here.
General
- A large meta-analysis showed two markers (CK5/6, GATA3) can subclassify ~90% of urothelial carcinoma into prognostic groups.[2]
Prognosis
Basal is bad.Cite error: Invalid <ref> tag; invalid names, e.g. too many
A simple classification of urothelial carcinoma by immunohistochemistry
| Urothelial carcinoma | |||||||||||||||||||||||||||||||||||||||||
| Luminal type GATA3 +ve (CK5/6 -ve) | Basal type CK5/6 +ve (GATA3 -ve) | ||||||||||||||||||||||||||||||||||||||||
| Genomically unstable p16 +ve | Urothelial-like p16 -ve | ||||||||||||||||||||||||||||||||||||||||
Notes:
- GATA3 positive and CK5/6 positive cases are classified as luminal.[1]
- GATA3 negative and CK5/6 negative are unclassified.[1]
Additional note:
IHC
Panel:
- CK5/6.
- GATA3.
- p16.
Important note:
- Twenty percent of the tumour cells is considered the cut-off for positive versus negative.[1]
Sign out
The immunoprofile (GATA3 POSITIVE, p16 POSITIVE, CK5/6 negative) is in keeping with UROTHELIAL CARCINOMA, LUMINAL TYPE, GENOMICALLY UNSTABLE.
The immunoprofile (GATA3 POSITIVE, p16 negative, CK5/6 negative) is in keeping with UROTHELIAL CARCINOMA, LUMINAL TYPE, UROTHELIAL-LIKE.
The immunoprofile (CK5/6 POSITIVE, GATA3 negative) is in keeping with UROTHELIAL CARCINOMA, BASAL TYPE.
Double positive
The immunoprofile (GATA3 POSITIVE, CK5/6 POSITIVE) would be compatible with UROTHELIAL CARCINOMA, LUMINAL TYPE.
See also
References
- ↑ 1.0 1.1 1.2 1.3 Olkhov-Mitsel E, Hodgson A, Liu SK, Vesprini D, Xu B, Downes MR (June 2021). "Three-antibody classifier for muscle invasive urothelial carcinoma and its correlation with p53 expression". J Clin Pathol. doi:10.1136/jclinpath-2021-207573. PMID 34103388.
- ↑ Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, Guo CC, Dinney C, Cogdell DE, Zhang S, Lee S, Lee JG, Weinstein JN, Baggerly K, McConkey D, Czerniak B (October 2016). "Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use". EBioMedicine 12: 105–117. doi:10.1016/j.ebiom.2016.08.036. PMC 5078592. PMID 27612592. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078592/.
- ↑ Sikic D, Keck B, Wach S, Taubert H, Wullich B, Goebell PJ, Kahlmeyer A, Olbert P, Isfort P, Nimphius W, Hartmann A, Giedl J (2017). "Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis". PLoS One 12 (6): e0179602. doi:10.1371/journal.pone.0179602. PMC 5478149. PMID 28632777. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478149/.